Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)

Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $250.00 price target on Natera (NASDAQ: NTRA).

The analyst commented: "We reiterate our BUY rating on Natera (NTRA) shares and maintain our price target at $250. Before the market open on Friday, December 5, NTRA announced it had
completed an all-stock transaction of Foresight Diagnostics for an upfront payment of $275 million, with an additional $175 million in earnouts. Foresight's CLARITY tumor-informed minimal residual disease (MRD) assay leverages its PhasED-Seq technology to track phased variants (PVs) to detect circulating tumor (ct)DNA in a manner that reduces background error rate. NTRA announced that an RUO version of Signatera with phased variant detection is now available and expects to launch it for clinical use in 2026. The integration of phased variants into the Signatera platform should further differentiate and strengthen test performance across solid tumors and Foresight's MRD expertise could accelerate NTRA's entry into blood cancer MRD. Overall, we believe Foresight strengthens NTRA's MRD leadership position. Natera could also benefit from non-MRD catalysts (e.g., guideline inclusion for 22q microdeletions, early cancer detection [ECD], etc.) over time. We believe NTRA remains undervalued."

For an analyst ratings summary and ratings history on Natera click here. For more ratings news on Natera click here.

Shares of Natera closed at $244.55 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Genco Shipping urges shareholders to reject Diana's $24.80 takeover bid
• Arm Holdings (ARM) PT Raised to $500 at Mizuho